VAXART
Vaxart is a clinical-stage company focused on developing oral recombinant protein vaccines based on its proprietary oral vaccine platform and direct-acting antivirals to treat infections that have limited therapeutic options. Vaxart’s oral vaccines are designed to generate broad and durable immune responses that protect against a wide range of infectious diseases and may be useful for the treatment of chronic viral infections and cancer. Vaxart’s oral vaccines are administered using a conven... ient room temperature-stable tablet, rather than by injection. Vaxart believes that tablet vaccines are easier to distribute and administer than injectable vaccines, and have the potential to significantly increase vaccination rates. Vaxart’s development programs include oral tablet vaccines that are designed to protect against norovirus, seasonal influenza and respiratory syncytial virus (RSV), as well as a therapeutic vaccine for human papillomavirus (HPV). Through the merger, Vaxart also acquired antiviral drug candidates, including teslexivir (BTA074), an antiviral treatment for condyloma caused by HPV types 6 and 11.
VAXART
Industry:
Biotechnology Health Care Medical Device
Founded:
2004-01-01
Address:
San Francisco, California, United States
Country:
United States
Website Url:
http://www.vaxart.com
Total Employee:
101+
Status:
Active
Contact:
8667032712
Email Addresses:
[email protected]
Total Funding:
138.67 M USD
Technology used in webpage:
IPhone / Mobile Compatible Viewport Meta Domain Not Resolving Apple Mobile Web Clips Icon Google Font API Google Tag Manager WordPress LetsEncrypt HSTS IPv6
Similar Organizations
Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals is a biotechnology company that focuses on the development of medicine to treat diseases with a genetic origin.
Asklepios BioPharmaceutical
Asklepios BioPharmaceutical is a biotechnology company developing adeno-associated virus (AAV) gene therapies for genetic disorders.
Attest Laboratories
Attest Laboratories is a biotechnology company that develops the next generation of biomarker test technology for healthcare providers.
Cedilla Therapeutics
Cedilla Therapeutics is a biotechnology company that develops targeted small molecules for the treatment of cancer and other diseases.
CEL-SCI
CEL-SCI is a biotechnology company developing immunotherapy products for the treatment of cancer and other infectious diseases.
CVRx
CVRx is a medical device company developing implantable technology for the treatment of high blood pressure.
Hilab
Hilab is a technology company that develops biomedical equipment and telemedicine technology for the humanization of health care.
Translate Bio
Translate Bio is a biotechnology company that specializes in biotechnology, RNA therapeutics, and rare diseases.
Soligenix
Soligenix is a biopharmaceutical company that develops biodefense vaccines and therapeutics to treat rare diseases.
ViewRay
ViewRay is a medical company that develops radiation therapy technology for the treatment of cancer.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2017-10-30 | Aviragen Therapeutics | Aviragen Therapeutics acquired by Vaxart | N/A |
Investors List
RA Capital Management
RA Capital Management investment in Post-IPO Equity - Vaxart
Sand Hill Angels
Sand Hill Angels investment in Venture Round - Vaxart
Sand Hill Angels
Sand Hill Angels investment in Series D - Vaxart
Sand Hill Angels
Sand Hill Angels investment in Series C - Vaxart
Sand Hill Angels
Sand Hill Angels investment in Series B - Vaxart
Care Capital
Care Capital investment in Series B - Vaxart
Quantum Technology Partners
Quantum Technology Partners investment in Series B - Vaxart
Life Science Angels
Life Science Angels investment in Series B - Vaxart
Mason Ng
Mason Ng investment in Series B - Vaxart
Sand Hill Angels
Sand Hill Angels investment in Series B - Vaxart
Key Employee Changes
| Date | New article |
|---|---|
| 2024-03-06 | Vaxart appoints Steven Lo as president, CEO, and director |
| 2022-12-19 | Vaxart Names Phillip Lee as Chief Financial Officer |
| 2022-02-14 | Vaxart Appoints Edward Berg as Senior Vice President and General Counsel |
| 2021-09-27 | Vaxart Appoints Dr. James F. Cummings as Chief Medical Officer |
Official Site Inspections
http://www.vaxart.com Semrush global rank: 2.59 M Semrush visits lastest month: 6.97 K
- Host name: 141.193.213.10
- IP address: 141.193.213.10
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Vaxart"
Vaxart - Wikipedia
Vaxart, Inc. is an American biotechnology company focused on the discovery, development, and commercialization of oral recombinant vaccines administered using temperature-stable tablets that can be stored and shipped without refrigeration, eliminating the need for needle injection. Its development programs for oral vaccine delivery (Vector-Adjuvant-Antigen Standardized Te…See details»
Vaxart - Crunchbase Company Profile & Funding
Vaxart is a clinical-stage company focused on developing oral recombinant protein vaccines based on its proprietary oral vaccine platform and direct-acting antivirals …See details»
Vaxart (VXRT) Company Profile & Description - Stock Analysis
4 days ago Company profile for Vaxart, Inc. (VXRT) with a description, list of executives, contact details and other key facts.See details»
Vaxart, Inc. (VXRT) Company Profile & Facts - Yahoo Finance
See the company profile for Vaxart, Inc. (VXRT) including business summary, industry/sector information, number of employees, business summary, corporate governance, key executives …See details»
Vaxart Company Profile - Office Locations, Competitors, Revenue
Oct 29, 2024 Vaxart has 1 employees at their 1 location and $28.7 m in annual revenue in FY 2024. See insights on Vaxart including office locations, competitors, revenue, financials, executives, …See details»
About Vaxart - Vaxart Inc.
About Vaxart Our Company Vaxart is a clinical-stage biotechnology company developing a range of oral recombinant pill vaccines based on our innovative delivery platform. We have proprietary technology, partnerships to accelerate our …See details»
OTC Markets Group Welcomes Vaxart, Inc. to OTCQX - Morningstar
Jul 8, 2025 Vaxart believes that its proprietary pill vaccine delivery platform is suitable to deliver recombinant vaccines, positioning the company to develop oral versions of currently marketed …See details»
Welcome - Vaxart Inc.
Vaxart is a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery platform. Its development programs currently include pill …See details»
Vaxart, Inc. – Investor Overview
The Investor Relations website contains information about Vaxart, Inc.'s business for stockholders, potential investors, and financial analysts.See details»
Mission - Vaxart Inc.
By providing a potentially superior solution to the global challenge posed by infectious viral diseases, Vaxart’s transformative vaccine pills can be the center of a new movement to make the world a …See details»
Join Us - Vaxart Inc.
Join the Vaxart Team We are a dynamic and diverse team united by a shared commitment to transforming global public health. If you are a talented and passionate individual excited about …See details»
Vaxart Provides Business Update and Reports Second Quarter 2025 ...
Jun 30, 2025 The Investor Relations website contains information about Vaxart, Inc.'s business for stockholders, potential investors, and financial analysts.See details»
Vaxart, Inc. –Vaxart Announces Trading on OTCQX Best Market
Jul 8, 2025 SOUTH SAN FRANCISCO, Calif., July 08, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX: VXRT) (“Vaxart” or the “Company”), a clinical-stage biotechnology company developing …See details»
Vaxart, Inc. – Press Releases
Jun 11, 2025 The Investor Relations website contains information about Vaxart, Inc.'s business for stockholders, potential investors, and financial analysts.See details»
US orders Vaxart to stop COVID-19 trial amid mRNA wind down
5 days ago Vaxart said on Wednesday it received an order to stop work on screening and enrollment for its COVID-19 mid-stage trial, joining multiple biotech companies that have lost …See details»
Vaxart, Inc. –Vaxart CEO Issues Letter to Stockholders
Aug 8, 2025 The Investor Relations website contains information about Vaxart, Inc.'s business for stockholders, potential investors, and financial analysts.See details»
US orders Vaxart to stop COVID-19 trial amid mRNA wind down
4 days ago Vaxart has been ordered to stop enrollment in its COVID-19 mid-stage trial as the US Department of Health and Human Services winds down mRNA vaccine development, signaling a …See details»
Vaxart outlines accelerated COVID-19 trial data timeline and plans ...
4 days ago Discover Vaxart's Q2 2025 earnings insights, featuring COVID-19 trial updates, norovirus progress, funding challenges, and strategic milestones.See details»
Pipeline - Vaxart Inc.
At Vaxart, we are revolutionizing how the immune system responds and the way vaccines are delivered with our oral pill vaccine. Our diverse pipeline of prophylactic and therapeutic vaccines …See details»
HHS Freezes Vaxart’s Oral COVID-19 Vaccine, Again - BioSpace
6 days ago The Department of Health and Human Services has slapped vaccine manufacturer Vaxart with another stop order for its next-generation oral COVID-19 vaccine, which the California …See details»